The profile is currenly unclaimed by the seller. All information is provided by CB Insights.


Series F | Alive

Total Raised


Last Raised

$121.72M | 1 yr ago

About PegBio

PegBio is a bio-pharmaceutical company engaging in manufacturing polyethylene glycol (PEG) and development of PEGylation technology leading to PEGylated drugs as putative new molecule entities (pNMEs) in China.

PegBio Headquarter Location

218 Xinghu Street SIP

Suzhou, Jiangsu,



Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing PegBio

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

PegBio is included in 1 Expert Collection, including Biopharma Tech.


Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

PegBio Patents

PegBio has filed 2 patents.

patents chart

Application Date

Grant Date


Related Topics




Diabetes, G protein coupled receptors, Peptide hormones, Hepatology, Nutrition


Application Date


Grant Date



Related Topics

Diabetes, G protein coupled receptors, Peptide hormones, Hepatology, Nutrition



Latest PegBio News

Global GLP-1 Receptor Agonist Market Research Report to 2027 - Featuring Novo Nordisk, PegBio and Sanofi Among Others

Apr 26, 2022

News provided by Share this article Share this article The Global GLP-1 Receptor Agonist Market size was estimated at USD 3,632.28 million in 2021, USD 4,016.94 million in 2022, and is projected to grow at a Compound Annual Growth Rate (CAGR) of 10.84% to reach USD 6,737.14 million by 2027. Competitive Strategic Window: The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period. FPNV Positioning Matrix: The FPNV Positioning Matrix evaluates and categorizes the vendors in the GLP-1 Receptor Agonist Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape. Market Share Analysis: The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits. The report provides insights on the following pointers: 1. Market Penetration: Provides comprehensive information on the market offered by the key players 2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets 3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments 4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players 5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments The report answers questions such as: 1. What is the market size and forecast of the Global GLP-1 Receptor Agonist Market? 2. What are the inhibiting factors and impact of COVID-19 shaping the Global GLP-1 Receptor Agonist Market during the forecast period? 3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global GLP-1 Receptor Agonist Market? 4. What is the competitive strategic window for opportunities in the Global GLP-1 Receptor Agonist Market? 5. What are the technology trends and regulatory frameworks in the Global GLP-1 Receptor Agonist Market? 6. What is the market share of the leading vendors in the Global GLP-1 Receptor Agonist Market? 7. What modes and strategic moves are considered suitable for entering the Global GLP-1 Receptor Agonist Market? Key Topics Covered:

  • Where is PegBio's headquarters?

    PegBio's headquarters is located at 218 Xinghu Street, Suzhou.

  • What is PegBio's latest funding round?

    PegBio's latest funding round is Series F.

  • How much did PegBio raise?

    PegBio raised a total of $143.72M.

  • Who are the investors of PegBio?

    Investors of PegBio include bioVENTURE, TF Capital, Yuanfeng Capital, Yunfeng Capital, Zhongxin Innovation Capital and 11 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.